Month: May 2026

Enhanced Cryopreservation of Therapeutically Relevant Cells

By

Reduced-DMSO cryopreservation workflows often compromise post-thaw viability, expansion, and functional cell attributes due to increased cellular stress during freeze/thaw. In a comparative study across T cells, mesenchymal stem cells (MSCs), and induced pluripotent stem cells (iPSCs), InVitria® evaluated whether recombinant human serum albumin (rHSA) could improve cryopreservation performance relative to plasma-derived HSA (pHSA) and albumin-free …

InVitria Presents ASGCT 2026 Data on rHSA for Lentiviral Vector Manufacturing

By

FOR IMMEDIATE RELEASE InVitria Presents New Data at ASGCT 2026 on Recombinant Human Serum Albumin for Higher Lentiviral Vector Titers and Improved Cell Therapy Manufacturing JUNCTION CITY, Kan., May 12, 2026 — InVitria, a global leader in chemically defined, animal-origin-free recombinant proteins for advanced therapy manufacturing, announced its participation in the American Society of Gene …